Specialty Guideline Management Prolia and Biosimilars
Customize your policy alerts
Sign up for cvs_caremark Policy 2026-A alerts
Get alerted when Policy 2026-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs specialty guideline management and prior authorization for Prolia (denosumab) and listed denosumab biosimilars for osteoporosis, glucocorticoid-induced osteoporosis, cancer-therapy-related bone loss, and rheumatoid arthritis when applicable coverage criteria are met.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.